Blood, Vol. 89 No. 12 (June 15), 1997:
pp. 4624-4627
Molecular Analysis of Eight Biochemically Unique Glucose-6-Phosphate Dehydrogenase Variants Found in Japan
By
Akira Hirono,
Hisaichi Fujii,
Toshikuni Takano,
Yasuko Chiba,
Yoichi Azuno, and
Shiro Miwa
From the Okinaka Memorial Institute for Medical Research, Tokyo; the Department of Transfusion Medicine, Tokyo Women's Medical College, Tokyo; the Department of Pediatrics, Iwate Medical University School of Medicine, Morioka; the First Department of Internal Medicine, Niigata University School of Medicine, Niigata; and the Department of Internal Medicine, Yamaguchi Rosai Hospital, Onoda, Japan.
 |
ABSTRACT |
We analyzed the molecular mutations of eight known Japanese glucose-6-phosphate dehydrogenase (G6PD) variants with unique biochemical properties. Three of them were caused by novel missense mutations: G6PD Musashino by 185 C
T, G6PD Asahikawa by 695 GA, and G6PD Kamiube by 1387 CT. Predicted amino acid substitutions causing asymptomatic variants G6PD Musashino (62 ProPhe) and G6PD Kamiube (463 ArgCys) were located in regions near the amino or carboxyl end of the polypeptide chain, whereas an amino acid change 232 CysTyr causing a class 1 variant G6PD Asahikawa was located in the region where amino acid alterations in some class 1 variants were clustered. The other five variants had known missense mutations, namely, G6PD Fukushima, 1246 GA, G6PD Morioka, 1339 GA, and G6PD Iwate, G6PD Niigata and G6PD Yamaguchi, 1160 GA, which cause variants, G6PD Tokyo, G6PD Santiago de Cuba, and G6PD Beverly Hills, respectively.
| |
INTRODUCTION |
SINCE THE WORLD HEALTH Organization (WHO) proposal of standard procedures for characterizing glucose-6-phosphate dehydrogenase (G6PD) variants in 1967,1 more than 400 G6PD variants have been identified by their biochemical properties.2 Efforts to characterize the diverse variant enzymes have proven fruitful in understanding some basic features of G6PD deficiency such as ethnic heterogeneity or relationships between functional abnormalities and clinical manifestations.3 On the other hand, the DNA mutations causing G6PD deficiencies have been analyzed since 1987,4 and nearly 100 molecular variants have so far been reported.5 It is well established that some of the biochemical variants bear an identical mutation, or that distinct mutations can cause a phenotypically identical variant.5 Indeed, of 52 unique biochemical variants, which have been studied at the DNA level, only 28 are molecularly unique.5
The tertiary structure of G6PD from Leuconostoc mesenteroides has recently been determined.6 A model of the tertiary structure of the human enzyme has been subsequently deduced, and it has shed some light on the pathogenesis of some mutations.7 Although biochemical characterization has lost its significance as a means of identifying variants, it still provides useful information about the functional abnormalities of variant enzymes. It is, therefore, important to reanalyze fully characterized biochemical variants using current molecular techniques and to evaluate the biochemical properties to elucidate structure-function relationships. We report here a molecular study of eight biochemically distinct variants in blood samples from Japanese individuals.
| |
MATERIALS AND METHODS |
G6PD variants.
We examined the G6PD variants, G6PD Musashino,8 G6PD Asahikawa,9 G6PD Iwate,10 G6PD Niigata,11 G6PD Fukushima,12 G6PD Morioka,13 G6PD Yamaguchi,12 and G6PD Kamiube14 in this study. Case histories of the patients and the biochemical properties of the variant enzymes have been reported elsewhere.8-14 The biochemical properties of the variants are summarized in Table 1. G6PD Musashino and G6PD Kamiube are asymptomatic variants found in a G6PD deficiency screening of healthy Japanese males. The other six variants belong to class 1. Chronic nonspherocytic hemolytic anemia was the only clinical manifestation of the patients, except for one with G6PD Niigata who was complicated by severe hemochromatosis of unknown etiology and died at age 25.
Preparation of genomic DNA.
Fresh blood samples were obtained from the patients with G6PD Iwate, G6PD Morioka, and G6PD Yamaguchi after obtaining their informed consent. Genomic DNA was isolated from the buffy coat and purified by standard means.15 Because fresh blood samples were no longer available for G6PD Musashino, G6PD Asahikawa, G6PD Fukushima, and G6PD Kamiube, genomic DNA of these variants was isolated from stored cellulose-treated blood as described.16 Genomic DNA of the patient with G6PD Niigata was isolated from a bone marrow smear that was the only available material from the patient. A glass slide with the bone marrow smear was soaked in running water for 1 hour to remove dust and contaminating DNA materials. The slide was dried, incubated with 600 µL of lysis solution (0.1 mg/mL proteinase K and 0.5% sodium dodecyl sulfate [SDS]) at 55°C for 1 hour, then the smeared cells were scraped into the solution with a spatula and gently mixed by pipetting. The cells were completely lysed by further incubation at 55°C for 3 hours. Genomic DNA was then purified by the standard method.15
Mutation analysis.
Synthetic oligonucleotide primers used for the polymerase chain reaction (PCR) and direct sequencing were as described.17 PCR-based single strand conformation polymorphism (PCR-SSCP) analysis18 was performed by our modified method17 using a mini gel system and ethidium bromide staining. Amplified exons were directly sequenced by an automated DNA sequencer using a dideoxy fluorescent dye termination protocol (Dye Terminator Cycle Sequencing Kit; Perkin Elmer, Norwalk, CT). The mutation was verified either by detecting the altered restriction site or by sequencing both strands. The position of each mutation was expressed using the cDNA numbers.
| |
RESULTS AND DISCUSSION |
The results of molecular studies are summarized in Table 2. DNA samples from G6PD Musashino, G6PD Asahikawa, G6PD Fukushima, G6PD Morioka, and G6PD Kamiube showed clear mobility shifts in various exons. Direct sequencing analyses showed the nucleotide substitution responsible for each single-strand conformation change. However, the exon fragments from G6PD Iwate, G6PD Niigata, and G6PD Yamaguchi showed no mobility shift. We sequenced the whole coding region of these variants and found a single nucleotide substitution in each of them.
Molecular analysis showed that G6PD Iwate, G6PD Niigata, and G6PD Yamaguchi all bore the same missense mutation 1160 GA originally identified in G6PD Beverly Hills.19 These are the second, the third, and the fourth Japanese unrelated cases with the 1160 GA mutation. The identical mutation has also been found in two Caucasian patients with G6PD Genova20 and G6PD Worcester21, respectively.5 The mutation destroys the cleavage site for Hha I. The mother of the patient with G6PD Niigata was confirmed heterozygous by the restriction analysis. Although these four variants share the same distinctive properties including slow electrophoretic mobility, increased Km nicotinamide adenine dinucleotide phosphate (NADP+) and marked heat instability, they vary in substrate specificity and pH optima. Because the biochemical characterization of G6PD Iwate, G6PD Niigata, and G6PD Yamaguchi were performed in the same laboratory using the same reagents and instruments, such variation is likely to be due to different degrees of denaturation of enzyme proteins. The extremely high utility rate of galactose-6-phosphate by G6PD Niigata is unique, and no other variants, except for G6PD Kobe22,23 that uses the substrate analogue 130 times faster than G6P, have this feature. The high utility of galactose-6-phosphate by G6PD Kobe appeared only after the enzyme was partially purified from hemolysate or a crude lymphoblastoid cell lysate from the patient (A. Hirono, unpublished observations, September 1983). This finding, as well as the marked heterogeneity of G6PD Niigata, G6PD Iwate, and G6PD Yamaguchi in galactose-6-phosphate utilization, suggests that the high activities of G6PD Kobe and G6PD Niigata towards the substrate analogue are not the direct outcome of a structural alteration caused by the mutations. Posttranslational factors are likely to participate in exposing their unique properties.
G6PD Fukushima had the missense mutation 1246 GA, which was originally identified in G6PD Tokyo.24 This mutation creates a new Sty I restriction site. The biochemical heterogeneity of G6PD Fukushima12 and G6PD Tokyo25 is minimal, namely the utility of deamino NADP+ is decreased in the former, and their having the same mutation is reasonable. The 1246 GA mutation is the most common class 1 mutation among Japanese, and it has been found in four unrelated families in addition to the present patient.17 The same mutation was also identified in a Scottish26 and an Italian27 family. The origin of the 1246 GA mutation in the Italian family is different from that in the Japanese family because the former was associated with a polymorphic CT mutation at nucleotide 131128 that was absent in the Japanese patients. Because there are few useful haplotype markers for the G6PD gene among Japanese, the origins of the identical mutations found in several unrelated families, such as the 1246 GA or the 1160 GA mutation, are difficult to evaluate at present.
The 1339 GA mutation identified in G6PD Morioka has been identified in G6PD Santiago de Cuba.29 This mutation creates a Pst I cleavage site. The heterogeneous biochemical properties are again evident in the two identical molecular variants. Although the deduced amino acid substitution 447 GlyArg predicts a slow electrophoretic mobility, which was confirmed in G6PD Santiago de Cuba, G6PD Morioka showed a normal electrophoretic mobility.
Molecular analysis of G6PD Asahikawa showed that this variant was molecularly, as well as biochemically unique. The 695 GA mutation found in G6PD Asahikawa is located in a region just downstream from the G6P binding site where several class 1 variants are clustered.7 Because this mutation does not alter any commercially available restriction enzyme sites, we examined the mutation in the proband's family members by SSCP analysis. While the mother was confirmed to be heterozygous, neither of the maternal grandparents carried the mutant allele, suggesting that the mutation of G6PD Asahikawa had arisen spontaneously in the germline of one of the proband's maternal grandparents. G6PD Asahikawa is distinctive in its unusual pH curve: an extremely high peak at pH 4.4 in addition to a low normal peak at 8.4. G6PD Clinic30,31 is the only other known variant with an unusual acidic pH optimum. The locations of the amino acid changes of these variants, 232 CysTyr (
G) in G6PD Asahikawa and 405 MetIle (M) in G6PD Clinic,31 are considerably apart both in the amino acid sequence and in the three-dimensional structure.7 The extraordinary properties of these variants remain to be further elucidated from the viewpoint of the structure-function relationships.
Two asymptomatic class 3 variants, G6PD Musashino and G6PD Kamiube, had unique missense mutations in exon 4 and 12, respectively. The 185 CT mutation in G6PD Musashino creates a new Taq I site, while the 1387 CT mutation in G6PD Kamiube does not affect any restriction sites. The heterozygosity of the probands' mothers was confirmed by either restriction or SSCP analysis. The missense mutation of G6PD Musashino predicts an amino acid substitution of 62 ProPhe. The tertiary structure model of the human G6PD suggests that the mutated residue of G6PD Musashino is located in a junction region between a helix (
a) and a sheet (B) in the coenzyme domain,7 which seems to be distant from either the substrate or the coenzyme binding site. The missense mutation of G6PD Kamiube predicts an amino acid substitution of 463 ArgCys. This position is also involved in the mutation that causes the class 2 variant G6PD Kaiping32 (1388 GA, 463 ArgHis). Because CG to TG and CG to CA mutations in the CpG dinucleotide occur at high frequency and some of the arginine residues are coded by codons CGX, identical arginine residues are often involved in different missense mutations and are changed to other amino acids. In human G6PD variants, the yielded residues are mainly cysteine and histidine. Five ArgCys/His substitutions have been reported: residue 81, Konan33/Lagosanto34; residue 285, Osaka5/Montalbano35; residue 387, Guadalajara36/Beverly Hills19; residue 454, Union37/Andalus38; and residue 463, Kamiube/Kaiping32. Except for the class 1 variants G6PD Guadalajara and G6PD Beverly Hills, the ArgCys variant seems to elicit less severe clinical expression than the ArgHis variant having the mutation in the same codon, although the significance of this phenomenon remains to be evaluated.
| |
FOOTNOTES |
Submitted December 2, 1996;
accepted February 6, 1997.
Supported in part by research grants from the Ministry of Education, Science, Sports and Culture, and the Ministry of Health and Welfare, Japan, and the Mitsui Life Social Welfare Foundation (Tokyo, Japan).
Address reprint requests to Akira Hirono, MD, Okinaka Memorial Institute for Medical Research, 2-2-2 Toranomon, Minato-ku, Tokyo 105, Japan.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
REFERENCES |
1. Betke K, Beutler E, Brewer GJ, Kirkman HN, Luzzatto L, Motulsky AG, Ramot B, Siniscalco M: Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. Report of a WHO scientific group. WHO Tech Rep Ser No. 366, 1967
2.
Beutler E,
Yoshida A:
Genetic variation of glucose-6-phosphate dehydrogenase: A catalog and future prospects.
Medicine
67:311,
1988[Medline]
[Order article via Infotrieve]
3. Luzzatto L, Mehta A: Glucose-6-phosphate dehydrogenase deficiency, in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease (ed 7). New York, NY, McGraw-Hill, 1995, p 3367
4.
Takizawa T,
Yoneyama Y,
Miwa S,
Yoshida A:
A single nucleotide base transition is the basis of the common human glucose-6-phosphate dehydrogenase variant A(+).
Genomics
1:228,
1987[Medline]
[Order article via Infotrieve]
5.
Beutler E,
Vulliamy T,
Luzzatto L:
Hematologically important mutations: Glucose-6-phosphate dehydrogenase.
Blood Cells Mol Dis
22:49,
1996[Medline]
[Order article via Infotrieve]
6.
Rowland P,
Basak AK,
Gover S,
Levy HR,
Adams MJ:
The three-dimensional structure of glucose 6-phosphate dehydrogenase from Leuconostoc mesenteroides refined at 2.0 Å resolution.
Structure
2:1073,
1994[Medline]
[Order article via Infotrieve]
7.
Naylor CE,
Rowland P,
Basak AK,
Gover S,
Mason PJ,
Bautista JM,
Vulliamy TJ,
Luzzatto L,
Adams MJ:
Glucose 6-phophate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme.
Blood
87:2974,
1996[Abstract/Free Full Text]
8.
Kumakawa T,
Suzuki S,
Fujii H,
Miwa S:
Frequency of glucose 6-phosphate dehydrogenase (G6PD) deficiency in Tokyo and a new variant: G6PD Musashino.
Acta Haematol Jpn
50:25,
1987
9.
Takizawa T,
Fujii H,
Takegawa S,
Takahashi K,
Hirono A,
Morisaki T,
Kanno H,
Oka R,
Yoshioka H,
Miwa S:
A unique electrophoretic slow-moving glucose 6-phosphate dehydrogenase variant (G6PD Asahikawa) with a markedly acidic pH optimum.
Hum Genet
68:70,
1984[Medline]
[Order article via Infotrieve]
10.
Kanno H,
Takano T,
Fujii H,
Tani K,
Morisaki T,
Hirono A,
Kumakawa T,
Ogura H,
Takahashi K,
Tsutsumi H,
Miwa S:
A new glucose-6-phosphate dehydrogenase variant (G6PD Iwate) associated with congenital non-spherocytic hemolytic anemia.
Acta Haematol Jpn
51:715,
1988
11.
Chiba Y,
Takizawa S,
Kishi K,
Hattori A,
Shibata A,
Matsumoto N,
Fujii H,
Miwa S:
A new glucose 6-phosphate dehydrogenase (G6PD) variant (G6PD Niigata) with chronic hemolysis and liver hemochromatosis.
J Jpn Soc Int Med (Nippon Naika Gakkai Zasshi)
78:41,
1989
12.
Miwa S,
Fujii H,
Nakatsuji T,
Ishida Y,
Oda E,
Kaneto A,
Motokawa M,
Ariga Y,
Fukuchi S,
Sasai S,
Hiraoka K,
Kashii H,
Kodama T:
Four new electrophoretically slow-moving glucose 6-phosphate dehydrogenase variants associated with congenital nonspherocytic hemolytic anemia found in Japan:Gd(-) Kurume, Gd(-) Fukushima, Gd(-) Yamaguchi and Gd(-) Wakayama.
Am J Hematol
5:131,
1978[Medline]
[Order article via Infotrieve]
13. Endo M, Takano T, Suzuki K, Tsutsumi H, Kumakawa T, Ogura H, Kanno H, Hirono A, Morisaki T, Tani K, Takahashi K, Fujii H, Miwa S: A new glucose-6-phosphate dehydrogenase variant (G6PD Morioka). Rinsho Ketsueki 28:377a, 1985 (suppl)
14.
Nakatsuji T,
Miwa S:
Incidence and characteristics of glucose 6-phosphate dehydrogenase variants in Japan.
Hum Genet
51:297,
1979[Medline]
[Order article via Infotrieve]
15.
Goossens M,
Kan YW:
DNA analysis in the diagnosis of hemoglobin disorders.
Methods Enzymol
76:805,
1981[Medline]
[Order article via Infotrieve]
16.
Hirono A,
Miwa S,
Fujii H:
Cellulose-treated blood is a good source of DNA for molecular analysis.
Am J Hematol
46:252,
1994[Medline]
[Order article via Infotrieve]
17.
Hirono A,
Miwa S,
Fujii H,
Ishida F,
Yamada K,
Kubota K:
Molecular study of eight Japanese cases of glucose-6-phosphate dehydrogenase deficiency by non-radioisotopic single-strand conformation polymorphism analysis.
Blood
83:3363,
1994[Abstract/Free Full Text]
18.
Orita M,
Suzuki Y,
Sekiya T,
Hayashi K:
Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.
Genomics
5:874,
1989[Medline]
[Order article via Infotrieve]
19.
Hirono A,
Kuhl W,
Gelbart T,
Forman L,
Fairbanks VF,
Beutler E:
Identification of the binding domain for NADP+ of human glucose-6-phosphate dehydrogenase by sequence analysis of mutants.
Proc Natl Acad Sci USA
86:10015,
1989[Abstract/Free Full Text]
20.
Gaetani GF,
Galiano S,
Melani C,
Miglino M,
Forni GL,
Napoli G,
Perrone L,
Ferraris AM:
A new glucose-6-phosphate dehydrogenase variant with congenital non spherocytic haemolytic anaemia (G6PD Genova).
Hum Genet
84:337,
1990[Medline]
[Order article via Infotrieve]
21.
Snyder LM,
Necheles TF,
Reddy WJ:
G-6-PD Worcester: A new variant, associated with X-linked optic atrophy.
Am J Med
49:125,
1970[Medline]
[Order article via Infotrieve]
22.
Fujii H,
Miwa S,
Tani K,
Takegawa S,
Fujinami N,
Takahashi K,
Nakayama S,
Konno M,
Sato T:
Glucose 6-phosphate dehydrogenase variants: A unique variant (G6PD Kobe) showed an extremely increased affinity for galactose 6-phosphate and a new variant (G6PD Sapporo) resembling G6PD Pea Ridge.
Hum Genet
58:405,
1981[Medline]
[Order article via Infotrieve]
23.
Hirono A,
Nakayama S,
Fujii H,
Miwa S:
Molecular abnormality of a unique Japanese glucose-6-phosphate dehydrogenase variant (G6PD Kobe) with a greatly increased affinity for galactose-6-phosphate.
Am J Hematol
45:185,
1994[Medline]
[Order article via Infotrieve]
24.
Hirono A,
Fujii H,
Hirono K,
Kanno H,
Miwa S:
Molecular abnormality of a Japanese glucose-6-phosphate dehydrogenase variant (G6PD Tokyo) associated with hereditary non-spherocytic hemolytic anemia.
Hum Genet
88:347,
1992[Medline]
[Order article via Infotrieve]
25.
Miwa S,
Ono J,
Nakashima K,
Abe S,
Kageoka T,
Shinohara K,
Isobe J,
Yamaguchi H:
Two new glucose 6-phosphate dehydrogenase variants associated with congenital nonspherocytic hemolytic anemia found in Japan: Gd(-) Tokushima and Gd(-) Tokyo.
Am J Hematol
1:433,
1976[Medline]
[Order article via Infotrieve]
26.
Mason PJ,
Sonati MF,
MacDonald D,
Lanza C,
Busutil D,
Town M,
Corcoran CM,
Kaeda JS,
Stevens DJ,
Al-Ismail S,
Altay C,
Hatton C,
Lewis DS,
McMullin MF,
Meloni T,
Paul B,
Pippard M,
Prentice AG,
Vulliamy TJ,
Luzzatto L:
New glucose-6-phosphate dehydrogenase mutations associated with chronic anemia.
Blood
85:1377,
1995[Abstract/Free Full Text]
27.
Cappellini MD,
Martinez di Montemuros F,
Fiorelli G:
Different origin of nt 1246 glucose-6-phosphate dehydrogenase mutation.
Blood
84:3592,
1994[Free Full Text]
28.
Beutler E,
Kuhl W:
The NT 1311 polymorphism of G6PD: G6PD Mediterranean mutation may have originated independently in Europe and Asia.
Am J Hum Genet
47:1008,
1990[Medline]
[Order article via Infotrieve]
29.
Vulliamy TJ,
D'Urso M,
Battistuzzi G,
Estrada M,
Foulkes NS,
Martini G,
Calabro V,
Poggi V,
Giordano R,
Town M,
Luzzatto L,
Persico MG:
Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia.
Proc Natl Acad Sci USA
85:5171,
1988[Abstract/Free Full Text]
30.
Vives-Corrons JL,
Pujades MA,
Petit J,
Colomer D,
Corbella M,
Aguilar I,
Bascompte JLA,
Merino A:
Chronic nonspherocytic hemolytic anemia (CNSHA) and glucose 6 phosphate dehydrogenase (G6PD) deficiency in a patient with familial amyloidotic polyneuropathy (FAP): Molecular study of a new variant (G6PD Clinic) with markedly acidic pH optimum.
Hum Genet
81:161,
1989[Medline]
[Order article via Infotrieve]
31.
Rovira A,
Vulliamy T,
Pujades MA,
Luzzatto L,
Vives-Corrons JL:
Molecular genetics of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Spain: Identification of two new point mutations in the G6PD gene.
Br J Haematol
91:66,
1995[Medline]
[Order article via Infotrieve]
32.
Chiu DTY,
Zuo L,
Chen E,
Chao L,
Louie E,
Lubin B,
Liu TZ,
Du CS:
Two commonly occurring nucleotide base substitutions in Chinese G6PD variants.
Biochem Biophys Res Commun
180:988,
1991[Medline]
[Order article via Infotrieve]
33.
Hirono A,
Fujii H,
Miwa S:
Molecular abnormality of G6PD Konan and G6PD Ube, the most common glucose-6-phosphate dehydrogenase variants in Japan.
Hum Genet
91:507,
1993[Medline]
[Order article via Infotrieve]
34.
Ninfali P,
Baronciani L,
Ruzzo A,
Fortini C,
Amadori E,
Dall'ara G,
Magnani M,
Beutler E:
Molecular analysis of G6PD variants in northern Italy: A study on the population from the Ferrara district.
Hum Genet
92:139,
1993[Medline]
[Order article via Infotrieve]
35.
Viglietto G,
Montanaro V,
Calabro V,
Vallone D,
D'Urso M,
Persico MG,
Battistuzzi G:
Common glucose-6-phosphate dehydrogenase (G6PD) variants from the Italian population: Biochemical and molecular characterization.
Ann Hum Genet
54:1,
1990[Medline]
[Order article via Infotrieve]
36.
Beutler E,
Westwood B,
Prchal JT,
Vaca G,
Bartsocas CS,
Baronciani L:
New glucose-6-phosphate dehydrogenase mutations from various ethnic groups.
Blood
80:255,
1992[Abstract/Free Full Text]
37.
Rovira A,
Vulliamy TJ,
Pujades A,
Luzzatto L,
Vives Corrons J-L:
The glucose-6-phosphate dehydrogenase (G6PD) deficiency variant G6PD Union (454 ArgCys) has a worldwide distribution possibly due to recurrent mutation.
Hum Mol Genet
3:833,
1994[Free Full Text]
38.
Vives-Corrons JL,
Kuhl W,
Pujades MA,
Beutler E:
Molecular genetics of the glucose-6-phosphate dehydrogenase (G6PD) Mediterranean variant and description of a new G6PD mutant, G6PD Andalus1361A.
Am J Hum Genet
47:575,
1990[Medline]
[Order article via Infotrieve]
Abstract
Introduction
Abstract